Zinc citrate

Phase 2Small molecule

UUniversity of Florida

Zinc citrate is one of 8 small molecule programs targeting Cervical Dystonia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical DystoniaRecruiting

Cervical DystoniaPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Cervical Dystonia

#DrugCompanyPhaseTrials

Botox

AbbVie

Approved

3 2

Dysport

Ipsen

Approved

1 3

Ingrezza

Neurocrine Biosciences

Phase 2

1 4

IPN10200

Ipsen

Phase 2

1 5

Corabotase

Ipsen

Phase 2

1 6

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 7

Zinc citrate

UUniversity of Florida

Phase 2

1 8

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Overactive Bladder (OAB)

NCT07405554

Phase 2Recruiting

Cervical Dystonia

NCT07140874

Clinical

Trials by Indication[1]

Cervical Dystonia1 trial

Zinc as an Adjunctive Therapy for Cervical Dystonia

Recruiting·UUniversity of Florida·Phase 2·NCT07140874·20 enrolled

Spasmodic Dysphonia1 trial

The Effect of Zinc Supplementation Prior to Botulinum Neurotoxin Type A Injection in the Treatment of Spasmodic Dysphonia

Completed·UUniversity of Florida·Preclinical·NCT05892770·32 enrolled

Overactive Bladder (OAB)1 trial

Effect of Zinc Supplementation on Botulinum Toxin for Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Trial

Recruiting·EEndeavor Health·Phase 2·NCT07405554·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Zinc citrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zinc citrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zinc citrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Florida

Zinc citrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Cervical Dystonia1 trial

Spasmodic Dysphonia1 trial

Overactive Bladder (OAB)1 trial

References

Drug Info

Quick Facts

Related News